This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in ...

Regulators approved the injection, which significantly cuts administration time versus the intravenous formulation, based on a Phase III comparison of the two.

We are honored to introduce KEYTRUDA SC, the first and only subcutaneous immune checkpoint inhibitor in Europe that can be administered in one minute every three weeks or in two minutes every six ...

Merck & Co, known as MSD outside of the USA and Canada, today announced that the European Commission (EC) has approved a new ...

Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...

A subcutaneously injected version of Merck cancer immunotherapy Keytruda is now FDA approved, a regulatory decision that gives patients a less burdensome dosing option and provides the pharmaceutical ...

Merck & Co. has won European Commission approval of a formulation of its blockbuster cancer drug Keytruda that can be injected under the skin. The Rahway, N.J., drugmaker on Wednesday said the green ...

Keytruda with paclitaxel, with or without Avastin, improved PFS and OS in PRROC patients, irrespective of PD-L1 status. The trial showed significant benefits in both CPS ≥1 and intention-to-treat ...

Merck (MRK) announced that the European Commission has approved a new subcutaneous, or under the skin, route of administration and a new ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...